<DOC>
	<DOCNO>NCT02982837</DOCNO>
	<brief_summary>To assess whether PEG-INF ( Peglyated - interferon ) Add-on therapy patient CHB achieve maintained viral suppression ( HBV DNA PCR ( polymerase chain reaction ) &lt; 200 last 3-6 month ) NA 's result increase rate HBV infection eradication ( HbsAg undetectable serological blood test without seroconversion HBs antibody ) .</brief_summary>
	<brief_title>To Study Effect Adding Pegylated Interferon ( PEG-INF ) Therapy Patients Diagnosed With Chronic Hepatitis B</brief_title>
	<detailed_description>Hepatitis B virus ( HBV ) infection remain global health care problem one third world 's population serological evidence expose virus 5 % global population ( 350-400 million ) chronically infect . About 15-40 % Patients chronic hepatitis B ( CHB ) infection develop complication liver cirrhosis , liver failure hepatocellular carcinoma ( HCC ) life time , result estimate 500,000 1.2 million death year . In Saudi Arabia , chronic hepatitis B remain serious medical problem , despite implementation mandatory HBV vaccination child since 1989 . According recent study conduct Saudi hospital , HBV account 49 % hepatitis case . Persistent viral replication associate disease progression liver fibrosis , cirrhosis development HCC . Currently two class drug available treatment CHB namely immunomodulatory therapy ( conventional &amp; pegylated interferon ( Pegasys ) PEG-IFN ) nucleoside/nucleotide analogue ( NA ) . Interferon ( IFN ) -α dual immunomodulatory antiviral effect first drug ( recombinant standard IFN- α ) license Chronic hepatitis B treatment 1990 's follow introduction nucleos ( ) ide analogue ( NA ) 1998 directly inhibit HBV polymerase provide effective treatment maintain viral suppression . With introduction pegylated interferon- α ( PEG-IFN ) 2005 allow convenient week dose interval equal superior treatment efficacy conventional ( IFN ) , interferon base therapy markedly improve utility . Due predominant immunomodulatory effect peginterferon ( PEG-IFN ) offer advantage higher sustain treatment response rate compare NA thus allow finite duration treatment . The NA act directly inhibit HBV polymerase result effective treatment maintain viral suppression ( HBV DNA PCR &lt; 200 last 3-6 month ) ) . However , long term NA therapy problem emergence viral resistance , long -term safety , cost patient compliance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Adults ≥18 &amp; &lt; 70 year gender . CHB NA 's maintained viral suppression ( HBV DNA PCR &lt; 200 last 36 month ) Patients measurable HBsAg quantitative level Patients HBV genotype . Patients either CHB e Ag positive eAg negative Patients sign inform consent inclusion study . Patients hepatitis Delta coinfection . patient negative pregnancy test child bear potential agree utilize strict birth control method enrol Patients follow characteristic consider trial : Decompensated liver Cirrhosis HCV ( hepatitis C virus ) HIV co infection . Autoimmune disorder like SLE ( Systemic lupus erythematosus ) , RA ( Rheumatoid Arthritis ) , AIH ( Autoimmune Hemolytic Anemia ) , ITP ( Immune thrombocytopenic purpura ) , psoriasis etc . Untreated psychiatric condition like depression alcohol drug abuse . Comorbid condition like chronic renal failure post renal/liver transplantation immunosuppressive therapy . Complicated diabetes mellitus advance heart failure . Pregnancy willing practice contraception . Known allergy Interferons . Concomitant treatment Telbivudine Evidence portal hypertension Biochemical ( Low Platelets le 100 ) , image UGI ( upper gastrointestinal ) endoscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>